Patents Assigned to Lennham Pharmaceuticals, Inc.
  • Publication number: 20240000799
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, deuterated androstenedione, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 4, 2024
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Publication number: 20230371555
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: April 21, 2023
    Publication date: November 23, 2023
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20230355632
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated paraxanthine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11666073
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: June 6, 2023
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11633371
    Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: April 25, 2023
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20230124138
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 20, 2023
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Patent number: 11547127
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: January 10, 2023
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11471469
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: October 18, 2022
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Publication number: 20220313630
    Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 6, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20220288083
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: November 24, 2021
    Publication date: September 15, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20220248720
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20220225642
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 21, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20220175796
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 9, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Patent number: 11344564
    Abstract: Provided herein are methods for the safe use of compositions comprising psilocin and prodrugs of psilocin for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: May 31, 2022
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Publication number: 20220160660
    Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 26, 2022
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11324762
    Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: May 10, 2022
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford Sippy
  • Patent number: 11202785
    Abstract: Provided herein are compositions (e,g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 21, 2021
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Publication number: 20210378266
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: November 16, 2020
    Publication date: December 9, 2021
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11000534
    Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: May 11, 2021
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford Sippy
  • Publication number: 20210068429
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy